CTOs on the Move

X-Vax Technology

www.x-vax.com

 
We`re a biotech company committed to developing vaccines against pathogens acquired by mucosal infection such as herpes. Our research leads us to believe that the new approach we`re taking could succeed in defeating herpes by inducing antibodies that mediate the killing of infected cells. We`re strongly committed to this fight, and so far our work has been supported with unprecedented data in multiple preclinical models.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

X-Vax Technology raised $56M on 07/23/2019

Similar Companies

Cambrian Biopharma

We partner with exceptional scientists to bring a new class of medicines to patients in need, built around understanding the deep science of the “Nine Hallmarks of Aging” with the potential to both treat and prevent today`s deadliest diseases.

Just-Evotec Biologics

Just Evotec Biologics is an integrated design company that delivers advanced biotherapeutics discovery, CDMO capabilities and FIH to commercial manufacturing. They focus on accelerating and expanding access to biotherapeutics through scientific and tec...

Humanetics

Humanetics Corp. is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angion

Angion Biomedica Corp. is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion`s lead product candidate, ANG-3777, is a small molecule designed to mimic the biological activity of hepatocyte growth factor (HGF) to activate the HGF/c-Met pathway, which has a central role in tissue repair and organ recovery. Enrollment is ongoing in a placebo-controlled Phase 3 registration trial examining the efficacy of ANG-3777 in reducing the severity of transplant-associated acute kidney injury, also known as delayed graft function, in patients at risk for kidney dysfunction. ANG-3777 is also in a Phase 2 clinical trial for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass. Angion is also developing ANG-3070, an orally-bioavailable small molecule, as a potential treatment for a variety of chronic fibrotic diseases sharing similar underlying disease-driving pathways identified and targeted using a precision-medicine approach.

Chi Botanic

Changing how we grow with plant cell cultures.